DavidCWeismanMD

Neurology • Abington, PA

Director of Abington Neurologic Association's Trial Center

Join to view full profile

Dr. Weisman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weisman's full profile

Already have an account?

Office
1151 Old York Rd
# 200
Abington, PA 19001
Phone+1 215-957-9250

Fax+1 215-957-9254

Summary

I'm a neurologist and trialist focusing on Alzheimer's. I founded and direct a clinical trial center investigating novel therapies in AD. We also target MS, pain, stroke and Parkinson's disease.

Education & Training

University of California (San Diego) Medical CenterFellowship, Vascular Neurology, 2004 - 2006
Yale-New Haven Medical CenterResidency, Neurology, 2001 - 2004
St Mary's Hospital and Medical CenterInternship, Internal Medicine, 2000 - 2001
Pennsylvania State University College of MedicineClass of 2000
Franklin and Marshall CollegeB.A., Philosophy, Cum Laude, 1996

Certifications & Licensure

PA State Medical License 2006 - 2024
CA State Medical License 2004 - 2006
CT State Medical License 2002 - 2004
American Board of Psychiatry and Neurology Neurology
National Board of Physicians and Surgeons Neurology
National Board of Physicians and Surgeons Vascular Neurology

Awards, Honors, & Recognition

Innovator Award, development of a computerized cognitive test Abington Memorial Hospital, 2014
IMS-III: site winner for shortest door to intravascular stroke treatment 2012
Alpha Epsilon Delta: Medical Honor Society 1996

Clinical Trials

Albumin in Acute Ischemic Stroke Trial Start of enrollment: 2006 Jun 01
Terminated
Phase 3
Interventional Management of Stroke (IMS) III Trial Start of enrollment: 2006 Aug 01
Terminated
Phase 3
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients Start of enrollment: 2008 Jun 01
Terminated
Phase 3
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients Start of enrollment: 2008 Jan 01
Terminated
Phase 3
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial Start of enrollment: 2010 May 28
Terminated
Phase 3
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients Start of enrollment: 2009 Dec 01
Terminated
Phase 3
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Start of enrollment: 2012 Apr 01
Completed
Phase 3
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis Start of enrollment: 2011 Sep 20
Completed
Phase 3
An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738) Start of enrollment: 2012 Nov 30
Terminated
Phase 2, Phase 3
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
Completed
Phase 2, Phase 3
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) Start of enrollment: 2013 Nov 05
Terminated
Phase 3
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) Start of enrollment: 2013 Oct 01
Terminated
Phase 2
A Study of Gantenerumab in Participants With Mild Alzheimer Disease Start of enrollment: 2014 Mar 27
Completed
Phase 3
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202) Start of enrollment: 2014 Mar 01
Completed
Phase 2
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Start of enrollment: 2014 Nov 01
Completed
Phase 3
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Start of enrollment: 2015 Mar 01
Completed
Phase 3
A Multicenter Assessment of ALD403 in Chronic Migraine Start of enrollment: 2014 Oct 01
Completed
Phase 2
Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease Start of enrollment: 2014 Nov 26
Terminated
Phase 2
Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I Start of enrollment: 2015 Apr 01
Completed
Phase 2, Phase 3
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Start of enrollment: 2015 May 01
Terminated
Phase 3
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type Start of enrollment: 2015 Jul 23
Completed
Phase 3
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type Start of enrollment: 2015 Dec 01
Recruiting
Phase 3
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis Start of enrollment: 2015 Oct 27
Completed
Phase 3
GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype Start of enrollment: 2015 Nov 01
Recruiting
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Start of enrollment: 2015 Nov 30
Terminated
Phase 2, Phase 3
An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia Start of enrollment: 2015 Oct 29
Terminated
Phase 2, Phase 3
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study Start of enrollment: 2015 Oct 01
Completed
Phase 3
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study Start of enrollment: 2015 Nov 30
Completed
Phase 3
Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study Start of enrollment: 2016 Jan 01
Completed
Phase 2
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). Start of enrollment: 2016 Mar 22
Terminated
Phase 3
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations Start of enrollment: 2016 Mar 03
Terminated
Phase 2
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis Start of enrollment: 2016 Sep 20
Completed
Phase 3
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. Start of enrollment: 2016 Aug 26
Completed
Phase 3
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
No longer available
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension Start of enrollment: 2016 Oct 01
Terminated
Phase 2, Phase 3
Safety of Intravenous Neridronic Acid in CRPS Start of enrollment: 2016 Dec 20
Completed
Phase 3
Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE) Start of enrollment: 2016 Nov 01
Terminated
Phase 2
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia Start of enrollment: 2016 Dec 20
Completed
Phase 2
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease Start of enrollment: 2016 Dec 01
Completed
Phase 1
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease. Start of enrollment: 2017 Apr 10
Terminated
Phase 3
Escitalopram for Agitation in Alzheimer's Disease Start of enrollment: 2018 Jan 03
Active, not recruiting
Phase 3
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Start of enrollment: 2017 Mar 29
Terminated
Phase 3
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease Start of enrollment: 2017 Feb 23
Completed
Phase 2
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Start of enrollment: 2017 Aug 03
Terminated
Phase 2, Phase 3
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) Start of enrollment: 2017 Nov 15
Terminated
Phase 2
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease Start of enrollment: 2017 Oct 04
Terminated
Phase 2
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) Start of enrollment: 2017 Nov 09
Completed
Phase 2
Tau Screening Study in Patients With Early Symptomatic AD Start of enrollment: 2017 Nov 21
Completed
Phase 2
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Start of enrollment: 2017 Sep 27
Completed
Phase 3
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) Start of enrollment: 2017 Dec 18
Completed
Phase 2
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Start of enrollment: 2018 Jun 06
Terminated
Phase 3
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease Start of enrollment: 2018 Apr 11
Terminated
Phase 3
Study of BHV-4157 in Alzheimer's Disease Start of enrollment: 2018 Jul 31
Completed
Phase 2
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease Start of enrollment: 2019 Jan 25
Completed
Phase 2
Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease Start of enrollment: 2019 May 16
Completed
Phase 2
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease Start of enrollment: 2019 May 22
Terminated
Phase 2
TRC-PAD Program: In-Clinic Trial-Ready Cohort Start of enrollment: 2019 Jun 04
Active, not recruiting
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Start of enrollment: 2019 Sep 30
Active, not recruiting
Phase 3
A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder Start of enrollment: 2020 Jul 09
Completed
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) Start of enrollment: 2021 Jan 26
Terminated
Phase 3
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) Start of enrollment: 2020 Jun 19
Active, not recruiting
Phase 3
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid Start of enrollment: 2020 Jul 14
Recruiting
Phase 3
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease Start of enrollment: 2020 Oct 27
Suspended
Phase 3
A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Start of enrollment: 2020 Nov 18
Terminated
Phase 2
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease Start of enrollment: 2021 Jan 22
Active, not recruiting
Phase 2
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) Start of enrollment: 2020 Nov 23
Completed
Phase 2
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects Start of enrollment: 2021 May 19
Active, not recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease Start of enrollment: 2021 May 05
Active, not recruiting
Phase 2
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Start of enrollment: 2023 Jun 28
Recruiting
Phase 2
ELND005 in Patients With Mild to Moderate Alzheimer's Disease Start of enrollment: 2007 Dec 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

210 citations
Decreased cerebrospinal fluid allopregnanolone levels in women with posttraumatic stress disorder.
Ann M. Rasmusson, Graziano Pinna, Prashni Paliwal, David Weisman, Christopher Gottschalk
Biological Psychiatry. 2006-10-01
3 citations
Generation and Characterization of a Human-Derived and Induced Pluripotent Stem Cell (iPSC) Line from an Alzheimer's Disease Patient with Neuropsychiatric Symptoms.
Ram Sagar, Cristina Zivko, Ariadni Xydia, David C Weisman, Constantine G Lyketsos
Biomedicines. 2023-12-15
58 citations
Dementia with Lewy Bodies
David Weisman, Ian G. McKeith
Seminars in Neurology. 2007-02-01

Journal Articles

Albumin administration in acute ischemic stroke: Safety analysis of the ALIAS Part 2 Multicenter Trial
Hill MD, Martin RH, Palesch YY, Moy CS, Tamariz D, Ryckborst KJ, Jones EB, Weisman D, Pettigrew C, Ginsberg MD, PLoS One, 1/1/2015
Questioning IA approach
Weisman D, Clinical Neurology News, 1/1/2009
Comment
Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA, Neurology, 1/1/2008
Interleukins, inflammation, and mechanisms of Alzheimer's disease
Weisman D, Hakimian E, Ho GJ, Vitam Horm, 1/1/2007
Decreased CSF Allopregnanolone in Women with PTSD
Rasmusson A, Pinna G, Paliwal P, Weisman D, Gottschalk C, Krystal J, Guidotti A, Arch Gen Psych, 1/1/2006
Managing patients with Alzheimer's disease
Corey-Bloom J, Yaari R, Weisman D, Neurology, 1/1/2006
Join now to see all

Books/Book Chapters

The Myth of an Afterlife: The Case against Life after Death
Chapter: Dissolution into Death: They Mind's last Symptoms Indicate Annihilation
Martin M, Augustine KRowman & Littlefield2015
The St. Martin's Guide to Writing 10
Chapter: Disposable Heroes
Weisman DBedford/Saint Martin's2013

Abstracts/Posters

Do microhemes beget microhemes?
Weisman D, Liu E, AAIC, London, 7/15/2017
Validation of the Philadelphia Cognitive Exam (P-Cog): A Rapid, Tablet-Computer Based Dementia Screening Test.
Weisman D, Khoury J, Kulandaivel K, Amberker D, Sleiman P, AAIC, 1/1/2015
Braak Stage Trumps Lewy Body Distribution.
Weisman D, Adame A, Taylor C, Thal L, Hansen L, AAN National Meeting

Lectures

Alzheimer's disease
1/1/2008
Alzheimer's disease: a long way from August D
1/1/2005
Shaken: Seizures for the Psychiatrist
1/1/2004
The Deprived Brain: Reorganization Following Deafferentation
1/1/2003
Cortical Signs, Thalamic Lesions, Corticothalamic Relations
1/1/2002
Join now to see all

Other

Disposable Heroes
Weisman D, Seed Magazine, Opinion
1/11/2011
Buddhism and the Brain.
Weisman D, Seed Magazine, Opinion
1/1/2011
Lost Consciousness
Weisman D, Esquire Russia
1/1/2011
Divided Minds, Specious Souls
Weisman D, Seed Magazine, Opinion
1/1/2010
Join now to see all

Press Mentions

FDA Advisors Endorse Rexulti for Agitation in Alzheimer's DementiaApril 14th, 2023
Can Alzheimer’s Be Detected with a Blood Test? This Pitt Scientist Says It May Help Identify Patients for a New DrugJanuary 4th, 2023
Decision Looms That Could Determine Fate of Alzheimer’s DrugDecember 31st, 2021
Join now to see all

Industry Relationships

National Coordinator, CREAD (Crenezumab in Alzheimer’s Disease) trial., Roche2016 - Present

External Links

Developed an Apphttp://p-cog.com/
Download herehttps://itunes.apple.com/us/app/p-cog-philadelphia-cognitive/id908942319?mt=8